Undisclosed NBD1 targeting CF therapeutic / Sionna Therap - LARVOL DELTA

Sionna Therapeutics to Present at the North American Cystic Fibrosis Conference (PRNewswire) - "Sionna Therapeutics...announced that it will present preclinical data on novel cystic fibrosis transmembrane conductance regulator (CFTR) modulator combinations at the Cystic Fibrosis Foundation's North American Cystic Fibrosis Conference (NACFC) 2022 to be held November 3-5 at the Pennsylvania Convention Center in Philadelphia. These combinations include Sionna's first-in-class molecules that target the first nucleotide-binding domain (NBD1) of CFTR, with the potential to enable full restoration of CFTR function in CF patients with the ΔF508 mutation."

Preclinical • Cystic Fibrosis • Genetic Disorders

Cystic Fibrosis Foundation Invests $5 Million in Sionna Therapeutics to Develop New CFTR Modulator Therapy (Businesswire) - "New modulators in development by the CF-specific company could provide unique treatment options for the underlying cause of cystic fibrosis for many people with the disease....The Cystic Fibrosis Foundation today announced its investment of $5 million in Sionna Therapeutics....The company is focused exclusively on developing cystic fibrosis transmembrane conductance regulator (CFTR) modulators, a type of therapy that treats the underlying cause of CF."

Financing • Cystic Fibrosis • Genetic Disorders

Sionna Therapeutics Launches with $111 Million Series B Financing to Advance Pipeline of Novel Small Molecules with the Potential to Fully Restore CFTR Function in Cystic Fibrosis (PRNewswire) - "Sionna Therapeutics...today announced the official launch of the company and the closing of a $111 million Series B financing. The round was led by OrbiMed with participation from funds advised by T. Rowe Price Associates, Inc., Q Healthcare Holdings, LLC., a wholly owned subsidiary of QIA, the sovereign wealth fund of Qatar, and previous investors including RA Capital, TPG's The Rise Fund, Atlas Venture, and the Cystic Fibrosis Foundation. Sionna has raised approximately $150 million to date....The company plans to advance development of a franchise of small molecules targeting NBD1 and complementary modulators, including NBD1's interface with the intracellular loop 4 (ICL4) region and the transmembrane domain 1 (TMD1) of CFTR. Sionna plans to submit Investigational New Drug applications (IND) for its first NBD1 targeted program, SION-638, and for its lead ICL4 program, SION-109, within the next 12 months."

Financing • IND • Cystic Fibrosis